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Abstract 
CAAX proteins are a group of proteins that undergo a three-step protein maturation process that renders the 
proteins carboxyl-terminus hydrophobic and prone to localize to cellular membranes, where they have their 
primary function. The first step in this process is called prenylation, which is the covalent attachment of a 
lipid, either a 15-carbon farnesyl or a 20-carbon geranylgeranyl lipid, to the carboxyl-terminal cysteine 
residue by the enzymes farnesyltransferase (FTase) and geranylgeranyltransferase type I (GGTase-I), 
respectively. 
Statins are inhibitors of HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthesis 
pathway, and are widely used in the treatment of hypercholesterolemia. They are thought to improve 
myocardial function by inhibiting GGTase-I- and FTase-mediated prenylation of the CAAX proteins RHOA 
and RAC1, two known mediators of cardiomyopathy. In the first paper of this thesis, we show that, contrary 
to popular belief, long-term statin administration causes reduced heart function, hypertrophic 
cardiomyopathy, and hyperactive RHOA in the hearts of wild-type mice. Similarly, we show that 
inactivation of the prenylation enzymes GGTase-I, FTase, or both, in heart muscle cells causes severe 
dilated cardiomyopathy. These findings indicate that statins and prenylation inhibitors might have the 
capacity to cause heart problems. 
In the second paper, we define the mechanism underlying a previous finding that inactivation of GGTase-I 
in mouse macrophages prevents prenylation of RHO family proteins, paradoxically causes them to become 
hyperactive, and that this leads to severe rheumatoid arthritis. We find that the RHO-protein RAC1 is 
responsible for the development of rheumatoid arthiritis. We further show that non-prenylated RAC1 exhibit 
an increased interaction with the effector proteins TIAM1 and IQGAP1 which trigger GTP loading, 
activation, excessive inflammatory signaling, and arthritis. Inactivation of RAC1 or IQGAP1 reduces the 
inflammatory signaling and markedly improves rheumatoid arthritis in GGTase-I deficient mice. We 
conclude that inhibiting prenylation of RAC1 stimulates effector interactions and cause excessive 
inflammatory signaling. This finding suggests that prenylation normally restrains innate immunity by 
limiting RAC1 effector interactions and its activation. 
Protein-altering germline mutations are a major cause of dilated cardiomyopathy (DCM). However, recent 
sequencing studies have shown that rare protein-altering variants are also present in individuals without 
reported DCM. This complicates the interpretation of genetic testing in the clinic, which is increasingly used 
for diagnosis. In the third paper, we analyzed genotype-phenotype correlations and variant prevalence in 41 
DCM-associated genes in a cohort of 176 Swedish DCM patients, and compared the variants to those of 
healthy reference individuals. We found 102 rare protein-altering variants, many of which were not 
previously reported, and further analysis revealed that harboring any variant was correlated with earlier 
onset of disease and reduced transplant-free survival. Comparing the number of variants found in DCM 
patients to rare variants in a healthy population showed that, while frameshift and nonsense variant were 
more common in DCM patients, the prevalence, pathogenicity scores, and location of missense variants 
were similar in both groups. These findings question the role of many putatively disease-causing variants 
and suggest that results from genetic testing should be interpreted with caution. 
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